All articles tagged with #diffuse large b cell lymphoma
A CART4-34 CAR-T therapy targets the IGHV4-34 gene in B-cell cancer, destroying lymphoma cells in mice as effectively as CD19 CAR-T while sparing healthy B cells and avoiding immune suppression; the approach could also be used to treat autoimmune conditions such as lupus, but human trials are needed.
Immune therapy, such as the bispecific antibody treatment Columvi, is offering new hope for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) when chemotherapy fails. Unlike chemotherapy drugs, antibody treatments like Columvi are more targeted and designed to spare healthy cells. Clinical trials have shown that Columvi can achieve remission in 43% of patients with DLBCL, and it has recently received approval from the FDA. Bispecific antibodies like Columvi attach to different receptor sites on cells, turning T cells into cancer-killing cells. While there is still more research to be done, bispecific antibody therapy could potentially revolutionize cancer treatment by providing more effective and tolerable options for patients.
Democratic Rep. Jamie Raskin has received a preliminary diagnosis of being "in remission" from diffuse large B-cell lymphoma and has finished chemotherapy. Raskin has a 90% prognosis of no relapse. He announced his cancer diagnosis in December 2020 and underwent outpatient treatment. Diffuse large B-cell lymphoma is a fast-growing but often treatable form of lymphoma.